Literature DB >> 22947138

Stability of a formalin-inactivated Rift Valley fever vaccine: evaluation of a vaccination campaign for cattle in Mozambique.

N Lagerqvist1, B Moiane, G Bucht, J Fafetine, J T Paweska, A Lundkvist, K I Falk.   

Abstract

In Africa and the Arabian Peninsula, outbreaks of Rift Valley fever (RVF) are characterized by abortions in gestating animals and high mortality rates among domestic ruminants. An immunization program using a formalin-inactivated vaccine was initiated in Mozambique in 2002 to control RVF in cattle. In this intervention, the vaccine must be transported for more than a week within the country before it can be administered to the animals, and it is practically impossible to maintain low storage temperatures during that time. Here, we evaluated the influence of transportation conditions on the efficacy of the vaccine. Sixty-three previously unvaccinated and RVF virus seronegative cattle were divided into four groups, which were given vaccine that had been stored for 1 week at 4°C (n=9, group A), at 25°C (n=8, group B), or alternating between 4 and 25°C (n=8, group C), or under the temperature conditions ordinarily occurring during transportation within Mozambique (n=38, group D). The antibody responses induced were monitored for 6-9 months and in some animals up to 21 months. Two immunizations (3 weeks apart) with the formalin-inactivated vaccine induced a long-lasting neutralizing antibody response that was still detectable up to 21 months later. The antibody titers in the animals did not differ significantly between the temperature-assigned vaccine groups A, B, and C, whereas they were significantly higher in group D. These results show that the formalin-inactivated RVF virus vaccine is stable, and, importantly, it is not adversely affected by the variation in temperature that ordinarily occurs during transport within Mozambique.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22947138     DOI: 10.1016/j.vaccine.2012.08.052

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Assessment of the control measures of the category A diseases of Animal Health Law: Rift Valley Fever.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Helen Clare Roberts; Barbara Padalino; Paolo Pasquali; Hans Spoolder; Karl Ståhl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Simon Gubbins; Alessandro Broglia; Inma Aznar; Yves Van der Stede
Journal:  EFSA J       Date:  2022-01-19

2.  Rift Valley Fever - assessment of effectiveness of surveillance and control measures in the EU.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Klaus Depner; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar Schmidt; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Paolo Pasquali; Helen Clare Roberts; Liisa Helena Sihvonen; Karl Stahl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Simon Gubbins; Sotiria-Eleni Antoniou; Alessandro Broglia; Josè Cortiñas Abrahantes; Sofie Dhollander; Yves Van der Stede
Journal:  EFSA J       Date:  2020-11-05

3.  Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative of severe disease.

Authors:  Petrus Jansen van Vuren; Sharon Shalekoff; Antoinette A Grobbelaar; Brett N Archer; Juno Thomas; Caroline T Tiemessen; Janusz T Paweska
Journal:  Virol J       Date:  2015-10-06       Impact factor: 4.099

4.  Serological evidence of rift valley fever virus among acute febrile patients in Southern Mozambique during and after the 2013 heavy rainfall and flooding: implication for the management of febrile illness.

Authors:  Eduardo Samo Gudo; Gabriela Pinto; Jacqueline Weyer; Chantel le Roux; Arcildo Mandlaze; Américo Feriano José; Argentina Muianga; Janusz Tadeusz Paweska
Journal:  Virol J       Date:  2016-06-08       Impact factor: 4.099

5.  High seroprevalence of Rift Valley fever phlebovirus in domestic ruminants and African Buffaloes in Mozambique shows need for intensified surveillance.

Authors:  Belisário Moiane; Lourenço Mapaco; Peter Thompson; Mikael Berg; Ann Albihn; José Fafetine
Journal:  Infect Ecol Epidemiol       Date:  2017-12-17

6.  Antibodies against Rift Valley fever virus in cattle, Mozambique.

Authors:  Nina Lagerqvist; Belisário Moiane; Lourenço Mapaco; José Fafetine; Sirkka Vene; Kerstin I Falk
Journal:  Emerg Infect Dis       Date:  2013-07       Impact factor: 6.883

Review 7.  Safety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review Study.

Authors:  Moataz Alhaj
Journal:  J Immunol Res       Date:  2016-09-04       Impact factor: 4.818

8.  Patterns of Rift Valley fever virus seropositivity in domestic ruminants in central South Africa four years after a large outbreak.

Authors:  Yusuf B Ngoshe; Alida Avenant; Melinda K Rostal; William B Karesh; Janusz T Paweska; Whitney Bagge; Petrus Jansen van Vuren; Alan Kemp; Claudia Cordel; Veerle Msimang; Peter N Thompson
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.